Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting
April 27, 2023 16:52 ET
|
Taysha Gene Therapies, Inc.
DALLAS, April 27, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for...
Taysha Gene Therapies Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
March 28, 2023 16:01 ET
|
Taysha Gene Therapies, Inc.
Initiated screening of first potential subject in Phase 1/2 REVEAL trial in Rett syndrome; dosing of first adult patient with TSHA-102 expected in H1 2023; submitted protocol amendment to allow for...
Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call and Webcast on March 28
March 15, 2023 16:01 ET
|
Taysha Gene Therapies, Inc.
DALLAS, March 15, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy and a 2023 Corporate Outlook
January 31, 2023 16:01 ET
|
Taysha Gene Therapies, Inc.
Type B end-of-Phase 2 meeting with U.S. Food and Drug Administration (FDA) provided additional clarity for TSHA-120 for the treatment of giant axonal neuropathy (GAN) ultra-rare disease program - FDA...
Taysha Gene Therapies Announces Executive Leadership Changes
December 16, 2022 18:19 ET
|
Taysha Gene Therapies, Inc.
Chair of the Board of Directors, Sean P. Nolan, appointed Chief Executive Officer Board Director, Sukumar Nagendran, M.D., appointed President and Head of R&D DALLAS, Dec. 16, 2022 (GLOBE...
Taysha Gene Therapies to Participate in JMP Securities Hematology and Oncology Summit
November 29, 2022 16:01 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Gene Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
$50 million strategic investment from Astellas Pharma to support development of TSHA-120 in giant axonal neuropathy (GAN) and TSHA-102 in Rett syndrome Proceeds from follow-on offering along with...
Taysha Gene Therapies to Release Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 8
November 02, 2022 07:00 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...
Taysha Announces Pricing of Public Offering of Common Stock
October 26, 2022 19:54 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (“Taysha”), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing...
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock
October 25, 2022 16:01 ET
|
Taysha Gene Therapies, Inc.
DALLAS, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene...